Global Ankylosing Spondylitis Drugs Market is Segmented By Drug Class (Tumor necrosis factor (TNF) blocker, Non-steroidal anti-inflammatory drugs, Disease-modifying antirheumatic drugs, Interleukin-17 (IL-17) inhibitor, Others), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Ankylosing Spondylitis Drugs Market Overview
The Global "Ankylosing Spondylitis Drugs Market" is expected to reach at a high CAGR during the forecast period (2024-2031).
Ankylosing spondylitis is a systemic inflammatory disease that primarily affects the spine. In ankylosing spondylitis, the joints, ligaments, and spine become inflamed. The inflammation leads to pain and stiffness in the lower back of the body and progress into the upper spine, neck, and chest.
Ankylosing Spondylitis Drugs Market Scope
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Drug Class, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights - Request Free Sample
Ankylosing Spondylitis Drugs Market Dynamics
The global ankylosing spondylitis drugs market growth is driven by the introduction of novel products and the entry of biosimilars, increasing prevalence of the disease, raising awareness about diagnostics and treatments for the disease. In addition, government initiatives and improving healthcare infrastructure.
The introduction of novel products and the entry of biosimilars coupled with the increasing prevalence of the disease is expected to drive market growth
Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a type of arthritis in which spine bones grow or fuse, causing the spine to become rigid. According to a study published in Oxford University Press, the number of cases in Europe was 1.30 to 1.56 million and 4.63 to 4.98 million in the Asia Pacific. The commercialization of novel products and increasing collaborations between companies are expected to accelerate market growth. For instance, in August 2019, Eli Lilly and Company received U.S. FDA approval for its product, Taltz injection 80 mg/mL, to treat active ankylosing spondylitis. Before this approval, the product was approved for active psoriatic arthritis and moderate to severe plaque psoriasis in March 2016 and December 2017, respectively. Moreover, in September 2018, Gilead Sciences, Inc. and Galapagos NV co-developed a product, Filgotinib, which has completed a phase 2 clinical trial to indicate moderately to severely active ankylosing spondylitis.
Moreover, the patent cliff has led to the entry of biosimilars into the market. These may improve patient access and contribute to market growth. For instance, in November 2019, the U.S. FDA approved Humira’s biosimilar, Abrilada, to treat certain indications, including ankylosing spondylitis.
The high cost of treatment is likely to hamper the market growth
As per the research of Novartis Pharmaceuticals Corporation, that provided insight into the direct medical costs associated with AS. The higher costs associated with AS were largely a result of increased medical outpatient services (mean cost $13,220 and $4,602 per patient per year) and outpatient pharmacy costs (mean cost $14,074 and $1,737 per patient per year). Outpatient pharmacy costs associated with AS included biologic therapies, other AS-related medications (e.g., anti-inflammatory drugs, antirheumatic drugs), antihypertensives, and antidepressants are likely to restrain the market growth.
COVID-19 Impact Analysis On Ankylosing Spondylitis Drugs Market
The COVID-19 pandemic is expected to impact the ankylosing spondylitis market due to disruptions in clinical studies, cancellation of elective procedures, and supply chain disruption. Ankylosing spondylitis drug suppliers faced several challenges such as travel restrictions, business closures, stay-at-home protocols, and employee illness or quarantines during the pandemic.
Many hospitals have cancelled or postponed elective surgeries worldwide to prevent cross-infection and meet the demands of coronavirus patients. For instance, University Medical Center and Sunrise Health in Las Vegas postponed elective surgeries to save bed capacity in 2020. According to the CovidSurg Collaborative in 2020, orthopedic procedures were cancelled most frequently, composing 26% of the total cancelled or postponed surgeries in 2020, which had a short-term negative impact on the market.
Ankylosing Spondylitis Drugs Market Segment Analysis
The cosentyx (secukinumab) segment is expected to hold the largest share in this market segment
Cosentyx (Secukinumab) is expected to be the fastest-growing segment over the forecast period. In January 2016, Cosentyx (also referred to by its generic name, Secukinumab), an IL-17 inhibitor approved by the FDA to treat ankylosing spondylitis. It's the first biologic of its kind to treat AS by targeting a molecule called IL-17A. It is administered as a subcutaneous injection is considered safer and more effective than NSAIDs. On October 24th 2019, Novartis received the European Commission approval for Cosentyx for non-radiographic axial spondylarthritis. The company further plans to submit the label update application to the U.S. FDA, and once it is approved, the product is projected to have significant growth over the forecast period.
Ankylosing Spondylitis Drugs Market Geographical Share
North America region holds the largest market share of the global ankylosing spondylitis drugs market
North America was the largest region that accounted for the highest share owing to high disease prevalence in the U.S. and Canada, commercial sales of branded drugs, and increasing product approvals. For instance, Renflexis (infliximab-abda) was approved in the U.S. in April 2017, and Ontruzant (trastuzumab-data) was approved in January 2019. The patent expiry of branded drugs has provided an opportunity for biosimilars. For instance, the patent expiry of Remicade in 2015 resulted in the introduction of Inflectra in 2016, Ixifi & Renflexis in 2017, and Avsola in 2019. Moreover, in October 2018, the patent of AbbVie’s proprietary product Humira expired in the E.U.
In addition, initiatives undertaken by major players support market growth in North America. In January 2019, Novartis AG and TrialSpark collaborated intending to increase patient access to clinical trials. This collaboration will shorten the enrollment timeline and help in the faster development of new therapies.
Ankylosing Spondylitis Drugs Market Companies and Competitive Landscape
The global ankylosing spondylitis drugs market is highly competitive with the presence of local as well as global companies. Some of the key players contributing to the market's growth include AbbVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Eli Lilly and Company, UCB, S.A, Johnson & Johnson Services, Inc, Merck & Co., Inc, Regeneron Pharmaceuticals and Bristol-Myers Squibb Company. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the software as a medical device globally. For instance, in May 2019, Abbvie Inc. announced the patent extension of its blockbuster drug, Humira, till 2023 in the U.S. after the settlement with Boehringer Ingelheim International GmbH. This deal with Boehringer enabled the company to maintain a monopoly in the U.S.
Global Ankylosing Spondylitis Drugs Market – Key Companies to Watch
Novartis AG
Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, established in 1996. The company has over 105,794 employees and operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units– Novartis Pharmaceuticals, which includes Novartis Gene Therapies, and Novartis Oncology – our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people worldwide access high-quality medicines.
Product Portfolio: COSENTYX (Secukinumab) is a fully human IgG1κ monoclonal antibody that selectively binds and neutralizes the proinflammatory cytokine interleukin-17A (IL17A). It is supplied as a sterile solution in a single-use pre-filled SensoReady pen and also supplied as a powder for solution for subcutaneous injection.
